* Regeneron Pharmaceuticals Inc reported quarterly adjusted earnings of $9.55 per share for the quarter ended in January, lower than the same quarter last year, when the company reported EPS of $10.09. The mean expectation of twenty three analysts for the quarter was for earnings of $10.09 per share. Wall Street expected results to range from $8.56 to $11.62 per share.
* Revenue fell 0.5% to $3.15 billion from a year ago; analysts expected $3.22 billion.
* Regeneron Pharmaceuticals Inc's reported EPS for the quarter was $6.27.
* The company reported quarterly net income of $722 million.
* Regeneron Pharmaceuticals Inc shares had fallen by 6.1% this quarter and gained 2.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 3% in the last three months.
* In the last 30 days, three analysts negatively revised earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 6 "hold" and 1 "sell" or "strong sell."
* Wall Street's median 12-month price target for Regeneron Pharmaceuticals Inc is $1,060.00
This summary was machine generated from LSEG data May 2 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 10.09 9.55 Missed
Dec. 31 2023 10.73 11.86 Beat
Sep. 30 2023 10.72 11.59 Beat
Jun. 30 2023 9.84 10.24 Beat
Comments